The Line Between Life and Death Cost a Dollar, and SAMHSA Just Cut It

Shreeta Waldon has been executive director of the Kentucky Harm Reduction Coalition long enough to know that the politics of overdose prevention are never fully stable. But the email she received on April 25 still landed differently. Her organization would be losing a $400,000 SAMHSA grant — the largest single funding stream that paid for roughly a dollar’s worth of prevention at a time, multiplied 48,465 times in the first quarter of 2026 alone.

Forty-eight thousand fentanyl test strips, handed out between January and March, in Kentucky. One state. Ninety days.

The day before Waldon got that email, SAMHSA’s acting director Chris Carroll sent what the agency calls a “Dear Colleague” letter to every grantee in its network. The two-page directive banned federal funds from purchasing fentanyl test strips, xylazine strips, sterile syringes, and something the letter called “overdose hotlines” — the services where someone using drugs alone can stay on the phone with a trained responder who can call 911 if they go silent. Also banned: sterile water provided to help people inject drugs more safely.

The letter did not cite any new research. It did not reference a change in the evidence base. It cited an executive order signed in July 2025 — one that declared SAMHSA money cannot fund programs that “only facilitate illegal drug use.”

“It doesn’t make sense,” Waldon told CBS News, “that one day something is evidence-based, and then because of political climate, it is no longer evidence-based.”

The line items they killed were the ones that don’t scale

Fentanyl test strips cost about one dollar each. They are not a complex intervention. A person gets one before they use; they dip it in a small amount of dissolved drug and water; two lines means negative, one line means fentanyl is present. Studies have consistently shown that people who test positive and find out change their behavior — they use less, they use more slowly, they don’t use alone, they are more likely to have naloxone nearby. The evidence base is not theoretical. It is the kind of evidence the CDC, the SAMHSA of two years ago, and the peer-reviewed public health literature have called a critical tool for exactly this moment in the overdose crisis.

The logic of the April 24 directive, as laid out by the Trump administration, is that distributing test strips “facilitates” illegal drug use — that making it less deadly is the same as encouraging it. The American Society of Addiction Medicine disagrees. Its president, addiction physician Stephen Taylor, called the directive a “clear step backward” for the field. “These are evidence-based interventions that save lives,” Taylor said in a statement. “We are deeply concerned about the consequences of removing them from the toolbox.”

The harm reduction field is used to political headwinds. What it’s less equipped to handle is the scale and speed of this particular reversal. Before April 24, roughly 45 states and Washington, D.C., had legalized fentanyl test strips — removing them from drug paraphernalia classifications so federal and state funds could flow toward them. The April 24 letter does not require states to re-criminalize strips. But it cuts off the funding stream that paid for the vast majority of public distribution.

At roughly a dollar per strip, the math is ruthless: $400,000 is 400,000 chances to know what you’re putting in your body.

A contradiction that lives inside the White House

Maritza Perez Medina, the Drug Policy Alliance’s director of federal policy, put it plainly when the directive dropped: “People are just astonished. There has been a lot of confusion about where this came from.”

Part of the confusion stems from a remarkable internal contradiction. The same week SAMHSA sent its letter, the White House released the Office of National Drug Control Policy’s 2026 National Drug Control Strategy. The ONDCP document — written by a different set of officials, approved by the same administration — includes this sentence: “Rapid test strips and similar technologies that detect fentanyl and other drugs are an important tool that should be legal and not considered drug paraphernalia.”

The same week SAMHSA sent its letter, the White House released the Office of National Drug Control Policy’s 2026 National Drug Control Strategy.

The left hand banning. The right hand endorsing. Neither hand acknowledging the other.

The incoherence matters because it signals that the April 24 directive was not the product of a considered policy review. It was the product of political messaging, implemented through the federal agency whose congressional mandate is to reduce harm from substance use. The ONDCP statement didn’t walk back the SAMHSA ban. The SAMHSA ban didn’t walk back the ONDCP endorsement. Both exist simultaneously. Grantees trying to interpret which one governs their federal money get a clear answer from the actual terms of their grants: the SAMHSA letter wins.

The broader funding context makes this even more stark. Before April 24, SAMHSA had already cancelled roughly $1.7 billion in block grant funding and cut an additional $350 million in addiction and overdose prevention spending — a series of cuts that began in January 2026 when the agency abruptly terminated and then reinstated thousands of grants in a 24-hour period that NPR called “chaos.” SAMHSA’s headcount has been reduced from approximately 900 employees to fewer than 450. This is not a targeted policy adjustment. It is a systematic dismantling of the federal harm reduction infrastructure at the precise moment that infrastructure had helped produce the biggest single-year decline in overdose deaths in two decades.

From 111,000 deaths in 2023 to approximately 68,000 in the twelve months ending November 2025. A 39 percent decline. It does not happen without the public health infrastructure doing its job.

Ohio is already running out

By June 5 — six weeks after the SAMHSA letter — Columbus Public Health went public with a simple problem: their test strips were nearly gone. The organization had distributed more than 50,000 fentanyl test strips over the preceding two years. Once those supplies were exhausted, it would need to rely on state and local health funding to continue — funding that is already being stretched by the same wave of federal cuts hitting every other behavioral health program in the state.

A’zhane Powell, founder and CEO of Fyrebird Recovery in South Carolina, lost a $4,000 grant in the same sweep that hit Waldon’s coalition. The amount is different. The principle is identical. “How far will it go,” Powell told CBS News, “until we’re back to square one again?”

That question describes the actual trajectory. Before 2021, fentanyl test strips were classified as drug paraphernalia under federal law, which meant organizations couldn’t distribute them with federal money. The Biden administration reversed that in April 2021, opening five years of expanding distribution infrastructure that gradually reached communities formal treatment had not. That five-year expansion is now running in reverse.

Lauren Kestner, division director at North Carolina’s Center for Prevention Services, described the situation as a fundamental shift in how prevention resources would have to be structured. Programs that had relied on SAMHSA block grants would need to find other revenue — state appropriations, private foundations, county health departments — at a time when those sources are absorbing their own federal reductions.

The American Society of Health-System Pharmacists formally opposed the ban on April 30, noting that it runs counter to evidence-based clinical practice and that pharmacists are particularly well-positioned to reach people at risk. That opposition has not changed the directive.

The supplies remain legal. The ban covers only federal funding for distributing them to the public. Naloxone — the overdose reversal medication — is explicitly excluded and remains eligible for federal support. So does testing for infectious diseases like hepatitis and HIV. The line the administration drew is between “reversing an overdose after it happens” and “helping someone know their drug is contaminated before they use it.” The distinction is coherent in exactly one policy framework: one where the goal is response to harm rather than prevention of it. That is not a harm-reduction framework. It is the opposite.

Naloxone — the overdose reversal medication — is explicitly excluded and remains eligible for federal support.

What this actually changes

The network of harm reduction programs that SAMHSA built through five years of categorical grants is not going to disappear overnight. Some organizations will find state funding. Some will find private donors. California and Nevada — states with strong public health infrastructure and large dedicated behavioral health budgets — are likely to maintain distribution programs largely intact.

Kentucky is not California. Ohio is not California.

For organizations in states with smaller Medicaid populations, weaker public health infrastructure, and less political appetite for harm reduction funding, the cutoff is close to categorical. Organizations that received $400,000 per year don’t find replacement funding in a month. Or two months. They find a different way to count their test strips.

The April 24 directive affects not just test strips but the entire harm reduction logic embedded in federal grants: the principle that meeting people where they are — even in active use — is a legitimate and fundable public health strategy. Sterile syringes reduce HIV and hepatitis C transmission. Overdose hotlines keep people alive long enough to decide they want treatment. Test strips reduce exposure to a drug supply that, per DEA data, is contaminated with fentanyl in a majority of samples across all substance classes. These are not controversial claims in the public health literature. They are becoming controversial claims in the federal funding apparatus.

The question for advocates, providers, and state health officials is whether the categorical grant structure that produced the 2021–2025 decline in overdose deaths can be replicated through a patchwork of state and local funding. The honest answer, from the organizations now holding one month’s worth of supplies and a phone full of unanswered foundation queries, is: not fast enough.

For people in recovery, for harm reduction workers, and for case managers working in the opioid use disorder space: the practical effect of the April 24 directive is that the organizations most likely to reach people before they need emergency treatment just lost their primary funding source. The gap is real. It is not yet closed.

Shreeta Waldon had approximately one month of supplies left when she spoke to reporters in late April. It is now mid-June. The strips run out when they run out. The people who would have received them are still using.

---

The overdose crisis does not wait for funding cycles, policy reviews, or congressional hearings. The people most likely to use a fentanyl test strip and change their behavior are, almost by definition, not the people walking into a treatment center tomorrow. They are the people for whom harm reduction was built — not as a substitute for treatment, but as the thing that keeps someone alive long enough to want it.

What the April 24 letter did, practically speaking, was cut the wire between those people and the tool most likely to interrupt a fatal dose. The political logic that produced it may yet be reversed. The overdose deaths that occur in the meantime will not.